Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
20 hedge funds and large institutions have $2.06M invested in Aptose Biosciences, Inc. in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
20% more capital invested
Capital invested by funds: $1.72M → $2.06M (+$338K)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
17% less funds holding
Funds holding: 24 → 20 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.94M |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$54.4K |
| 3 |
OP
ORG Partners
Roanoke,
Indiana
|
+$4.51K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$950 |
| 5 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
+$238 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Annandale Capital
Dallas,
Texas
|
-$44K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$42.6K |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$12.7K |
| 4 |
Morgan Stanley
New York
|
-$4K |
| 5 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$2.38K |
APTO Hedge Fund Activity: Q2 2024 in Review
20 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2024, worth a combined $2.06M — up 20% from $1.72M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of APTO and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.94M. The largest seller was Annandale Capital, exiting entirely with an estimated $44K sold.
- 20 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2024, down from 24 in Q1 2024.
- Funds reported $2.06M of Aptose Biosciences, Inc. stock for Q2 2024, up 20% quarter-over-quarter.
- 2 funds opened new Aptose Biosciences, Inc. positions in Q2 2024 and 5 closed out, a net change of -3 holders.
- The largest Aptose Biosciences, Inc. buyer in Q2 2024 was Armistice Capital, an estimated $1.94M added.
- The largest Aptose Biosciences, Inc. seller in Q2 2024 was Annandale Capital, an estimated $44K sold.
Based on aggregated 13F filings for Q2 2024.